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GOVERNOR PATRICK CELEBRATES GRAND 
OPENING OF PFIZER’S NEW R&D FACILITY ON SIXTH 
ANNIVERSARY OF LIFE SCIENCES INITIATIVE  
Pfizer moves into Kendall Square with new 280,000 sq. foot facility 
CAMBRIDGE – Monday, June 16, 2014 – On the sixth anniversary of his signing into 
law the Massachusetts Life Sciences Initiative, Governor Deval Patrick today joined 
Pfizer leadership, life sciences leaders and local and state officials to celebrate the 
grand opening of Pfizer’s new 280,000 square foot facility in Kendall square. 
 
“It is fitting that on the sixth anniversary of the Life Sciences Initiative becoming law, we 
are here celebrating the continued growth of one of our leading Life Sciences 
companies,” said Governor Patrick. “I congratulate Pfizer on their expansion and look 
forward to their continued contributions to our thriving Life Sciences community.” 
Led by Pfizer Group Vice President of BioTherapeutics R&D, José-Carlos Gutiérrez-
Ramos, Ph.D, the new laboratory facilities, located in the heart of Kendall Square, are 
leased from the Massachusetts Institute of Technology (MIT). Pfizer scientists will work 
in state-of-the-art lab space on a range of clinical programs across several therapeutic 
areas, including inflammation, immunoscience, rare disease, cardiovascular and 
metabolic diseases and neuroscience.    
 
“Our innovation economy is fueling our recovery and is creating economic opportunity 
throughout the Commonwealth,” said Secretary of Housing and Economic Development 
Greg Bialecki. “We congratulate Pfizer on its expansion and look forward to its 
continued growth and success here in Massachusetts.” 
 
In addition to the new Cambridge R&D hub, Massachusetts is home to Pfizer’s research 
and manufacturing site in Andover and is the global headquarters for Pfizer’s Centers 
for Therapeutic Innovation (CTI) in Boston. By establishing collaborations with 
institutions working on novel and cutting-edge research, CTI’s model is designed to 
build an innovative network for drug discovery, with the goal of bringing new, targeted 
therapies to patients quickly.  
“Pfizer’s unified presence in Cambridge reinforces our 15-year commitment to 
Massachusetts’ Life Sciences community,” said Mikael Dolsten, M.D., Ph.D., President 
of Research and Development at Pfizer. “Our goal in Kendall Square is to nurture 
collaborative and innovative science that can translate into new therapies for 
patients. Our proximity to the scientific brain trust that exists in this area, with world-
renowned academic, medical and research facilities opens endless possibilities to 
advance breakthrough therapies.” 
Today marks the sixth anniversary of Governor Patrick signing the Life Sciences 
Initiative, a ten-year, $1 billion investment in the growth of the state’s life sciences 
sectors. Since then, the Massachusetts Life Sciences Center has invested or committed 
$535 million to fund translational research, company formation and growth, workforce 
development and infrastructure, leveraging an additional $1.5 billion from outside 
sources. These investments have helped Massachusetts emerge over the past six 
years as the undisputed global leader in life sciences. 
"On behalf of the Center, I would like to extend our warmest congratulations to Pfizer on 
its expansion into Kendall Square,” said Susan Windham Bannister, Ph.D., President 
and Chief Executive Officer of the MLSC. “Massachusetts has become a magnet for 
major investment by the world’s leading biopharmaceutical companies, and we are 
excited that Pfizer sees strategic value in expanding here. Pfizer is an industry giant and 
adds enormously to our life sciences community in the Commonwealth.”  
“The value of research and development such as Pfizer’s is seen in gorgeous graphic 
terms every day,” said Representative Marjorie C. Decker. “It is seen in the patients who 
survive and thrive beyond what would have been bleak expectations even a handful of 
years ago. Attracting excellent life sciences companies and watching them expand is a 
core commitment that we policy and lawmakers continue to hold dear in Cambridge and 
the Commonwealth. We salute the fruits of your labors, Pfizer.”   
“I’m happy that a global biopharmaceutical leader like Pfizer continues to invest in the 
City of Cambridge,” said Representative Timothy J. Toomey. “Governor Patrick and 
Speaker DeLeo’s commitment to public investment in innovation has created a robust 
biotech industry in Massachusetts. I’m confident that Pfizer’s strong R&D organization 
will ensure that even more high skilled jobs will be created in Cambridge as well as lead 
to the development of critical new technologies and medicines that will benefit people 
worldwide.” 
A March 2013 report by The Boston Foundation showed that the Patrick 
Administration’s investments in the life sciences sector are making a measurable impact 
on job creation and spurring economic growth across the Commonwealth. The report 
also encouraged continued funding of the Life Sciences Initiative. The research found 
that over the last 10 years the state’s life sciences cluster has created jobs in 
Massachusetts at a faster pace than any other industry sector in the Commonwealth, 
and since 2008, Massachusetts has overtaken all competitor states in the rate of life 
sciences job creation. The report also commended the MLSC for its administrative 
efficiency and sound judgment in its investments and applauded the Governor and the 
Legislature for their foresight in creating the Center. 
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